Trial reportThe New England journal of medicine2023
Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
2 registry-linked trialsOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
19.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis
The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing Sexually Transmitted Diseases (Gonorrhea, Chlamydia, Syphilis) Among Men Who Have Sex With Men in Bangkok, Thailand.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024Guideline
- Oral preexposure prophylaxis use and the risk of bacterial sexually transmitted infections and HIV among African women: A prospective observational cohort study.PLoS medicine · 2026Trial
- Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis.The Journal of infectious diseases · 2026Trial
- Understanding barriers and facilitators to doxycycline post-exposure prophylaxis adherence among young women in western kenya: a qualitative study.BMC infectious diseases · 2025Trial
- An antibody-drug conjugate active against antibiotic-resistantProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Comparing Phenotypic Susceptibility Profiles of Neisseria gonorrhoeae for Tetracycline and Doxycycline.Sexually transmitted diseases · 2026Article
- Doxycycline Postexposure Prophylaxis in the Dominican Republic: Investigating Healthcare Provider Knowledge, Attitudes, and Practices in a Caribbean Clinical Setting.Sexually transmitted diseases · 2026Article
- Plasmids inClinical microbiology reviews · 2026Review
- Formulation Development of Topical Inserts Containing Doxycycline and Doxycycline Combined with Tenofovir Alafenamide and Elvitegravir for the Prevention of Sexually Transmitted Infections.AAPS PharmSciTech · 2026Article
- Engagement in Care and Sexually Transmitted Infection Screening Among Patients Prescribed Doxycycline Postexposure Prophylaxis at a Midwestern HIV/Preexposure Prophylaxis Clinic.Open forum infectious diseases · 2026Article
- Article
- Post-exposure prophylaxis with antibiotics to prevent sexually transmitted infections.The Cochrane database of systematic reviews · 2026Article
- Awareness, Usage and Perceptions of Doxycycline Post-Exposure Prophylaxis (doxyPEP) for Prevention of Sexually Transmitted Infections in Australia: Insights From a National Cross-Sectional Survey.The Medical journal of Australia · 2026Article
- Doxy-PEP interest, awareness, and use among sexual and gender minorities in Brazil, Mexico, and Peru: findings from a web-based survey.Lancet regional health. Americas · 2026Article
- Perspective on the pathogenic Neisseria: milestones, challenges, and future directions.NPJ vaccines · 2026Review
- Correlates of asymptomatic sexually transmitted infections among marginalized women in the Dominican Republic.International journal of STD & AIDS · 2026Article
- Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Impact and cost-effectiveness of doxycycline post-exposure prophylaxis in Australian men who have sex with men.Nature communications · 2026Article
- Southern African HIV Clinicians Society guideline on doxycycline post-exposure prophylaxis to prevent bacterial sexually transmitted infections.Southern African journal of HIV medicine · 2026Article
- A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome.Infectious diseases and therapy · 2026Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 3 institutions in 2 countries.
Jenell StewartFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).ORCID 0000-0002-8587-1096
Kevin OwareFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Deborah DonnellFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Lauren R VioletteFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Josephine OdoyoFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Olusegun O SogeFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Caitlin W ScovilleFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Victor OmolloFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Felix O MogakaFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Fredericka A SesayFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
R Scott McClellandFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Matthew SpinelliFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Monica GandhiFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Elizabeth A BukusiFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
Jared M BaetenFrom the Division of Infectious Diseases, Hennepin Healthcare Research Institute, and the Department of Medicine, University of Minnesota - both in Minneapolis (J.S.); Kenya Medical Research Institute, Kisumu (K.O., J.O., V.O., F.O.M., E.A.B.); Fred Hutchinson Cancer Research Center (D.D.) and the Departments of Epidemiology (L.R.V., F.A.S., R.S.M.), Global Health (O.O.S., C.W.S., R.S.M., E.A.B., J.M.B.), Medicine (Infectious Diseases) (L.R.V., O.O.S., R.S.M., J.M.B.), and Obstetrics and Gynecology (E.A.B.), University of Washington, Seattle; and the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco (M.S., M.G.).
dPEP Kenya Study Team
University of Washington · USUniversity of California, San Francisco · USUniversity of Minnesota · US
Funding
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6MPrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxisR01AI145971 · NIAID · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED, BUKUSI, ELIZABETH ANNE · 2019 to 2023
$4.0M“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2MRandomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEPR01AI186641 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPINELLI, MATTHEW A. · 2024 to 2025
$1.6MUnderstanding STI and HIV prevention adherence among Kenyan womenK23MH124466 · NIMH · UNIVERSITY OF WASHINGTON · PI STEWART, JENELL · 2020 to 2024
$939kNIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI145971NIAID NIH HHS R01 AI186641NIAID NIH HHS R37 AI098472NIH HHS 3R01AI098472NIH HHS K23MH124466NIH HHS R01AI45971NIMH NIH HHS K23 MH124466
Abstract
backgroundDoxycycline postexposure prophylaxis (PEP) has been shown to prevent sexually transmitted infections (STIs) among cisgender men and transgender women, but data from trials involving cisgender women are lacking.
methodsWe conducted a randomized, open-label trial comparing doxycycline PEP (doxycycline hyclate, 200 mg taken within 72 hours after condomless sex) with standard care among Kenyan women 18 to 30 years of age who were receiving preexposure prophylaxis against human immunodeficiency virus (HIV). The primary end point was any incident infection with
resultsA total of 449 participants underwent randomization; 224 were assigned to the doxycycline-PEP group and 225 to the standard-care group. Participants were followed quarterly over 12 months. A total of 109 incident STIs occurred (50 in the doxycycline-PEP group [25.1 per 100 person-years] and 59 in the standard-care group [29.0 per 100 person-years]), with no significant between-group difference in incidence (relative risk, 0.88; 95% confidence interval [CI], 0.60 to 1.29; P = 0.51). Among the 109 incident STIs, chlamydia accounted for 85 (78.0%) (35 in the doxycycline-PEP group and 50 in the standard-care group; relative risk, 0.73; 95% CI, 0.47 to 1.13). No serious adverse events were considered by the trial investigators to be related to doxycycline, and there were no incident HIV infections. Among 50 randomly selected participants in the doxycycline-PEP group, doxycycline was detected in 58 of 200 hair samples (29.0%). All
conclusionsAmong cisgender women, the incidence of STIs was not significantly lower with doxycycline PEP than with standard care. According to hair-sample analysis, the use of doxycycline PEP among those assigned to receive it was low. (Funded by the National Institutes of Health; dPEP ClinicalTrials.gov number, NCT04050540.).
Indexed as
Anti-Infective AgentsChlamydia InfectionsDoxycyclineGonorrheaPre-Exposure ProphylaxisSyphilisAdolescentAdultChlamydia trachomatisDrug MonitoringFemaleHairHIV InfectionsHumansKenyaNeisseria gonorrhoeaeAnti-Infective AgentsDoxycycline
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04050540ClinicalTrials.gov
NCT07397403ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.